Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J)
暂无分享,去创建一个
K. Ikari | H. Yamanaka | E. Inoue | Yoshiya Tanaka | Kazuyoshi Saito | T. Takeuchi | T. Mochizuki | H. Nagasawa | S. Iwata | H. Kameda | M. Nawata | N. Sekiguchi | E. Sato | K. Amano | K. Saito
[1] H. Yamanaka,et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2) , 2008, Modern rheumatology.
[2] H. Yamanaka,et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[3] D. M. van der Heijde,et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.
[4] H. Yamanaka,et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM) , 2007, Modern rheumatology.
[5] T. Takeuchi,et al. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab , 2006, Modern rheumatology.
[6] H. Yamanaka,et al. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values , 2006, Annals of the rheumatic diseases.
[7] N. Miyasaka,et al. Official Japanese guidelines for the use of infliximab for rheumatoid arthritis , 2005 .
[8] D. M. van der Heijde,et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.
[9] H. Imhof,et al. Radiological progression of joint damage in a longitudinal cohort of early DMARD‐treated rheumatoid arthritis patients followed for 10 years , 2004, Scandinavian journal of rheumatology.
[10] P. Lipsky,et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.
[11] D. M. van der Heijde,et al. Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis , 2002, Annals of the rheumatic diseases.
[12] S. Gabriel,et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. , 2002, Arthritis and rheumatism.
[13] F. Wolfe,et al. Premature mortality in patients with rheumatoid arthritis: evolving concepts. , 2001, Arthritis and rheumatism.
[14] D. M. van der Heijde,et al. Minimal clinically important difference in plain films in RA: group discussions, conclusions, and recommendations. OMERACT Imaging Task Force. , 2001, The Journal of rheumatology.
[15] G. Panayi,et al. Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.
[16] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[17] A Woolf,et al. The links between joint damage and disability in rheumatoid arthritis. , 2000, Rheumatology.
[18] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[19] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[20] P. Bacon,et al. Progression of radiological changes in rheumatoid arthritis. , 1984, Annals of the rheumatic diseases.
[21] F. Breedveld,et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.
[22] D. Cosgrove,et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[23] H. Hashimoto,et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. , 2006, The Journal of rheumatology.
[24] N. Miyasaka,et al. Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. , 2005, Modern rheumatology.
[25] M. Boers,et al. Minimal Clinically Important Difference in Plain Films in RA : Group Discussions , Conclusions , and Recommendations , 2002 .
[26] M. Feldmann,et al. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.
[27] L. Ivashkiv. Cytokine expression and cell activation in inflammatory arthritis. , 1996, Advances in immunology.
[28] R. Maini,et al. The Role of Cytokines in Rheumatoid Arthritis , 1996, Journal of the Royal College of Physicians of London.
[29] T. Pincus. Long-term outcomes in rheumatoid arthritis. , 1995, British journal of rheumatology.